Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Faenza – page 7

1 309 clinical trials in Faenza, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Faenza at a glance
1 309
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 309 trials in Faenza

Open in trial search

A study to evaluate the safety and effectiveness of rilvegostomig, ramucirumab, and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:Astrazeneca AB

Anaemia+1

Recruiting

A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa
  • Sponsor:Takeda Development Center Americas Inc.

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on the Effects of Acetylcarnitine Hydrochloride in Patients with Amyotrophic Lateral Sclerosis (ALS)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcarnitine hydrochloride
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Study on the Effectiveness of ADT with or without Darolutamide in Men with Newly Diagnosed Metastatic Prostate Cancer and Limited Functional Ability

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Unicancer

Phase 3 Study of Enfortumab Vedotin plus Pembrolizumab in Adults with Muscle‑Invasive Bladder Cancer Ineligible for Cystectomy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Pfizer Inc.

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Phase 3 Study of Pridopidine Hydrochloride for Safety and Efficacy in Adults with Huntington’s Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pridopidine hydrochloride
  • Sponsor:Ferrer Internacional S.A.

A Study of Baricitinib to Delay Type 1 Diabetes in Children and Adults at Risk of Developing the Disease

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

IgA nephropathy

Recruiting

Study of ARGX-121 to Reduce Proteinuria in Adults with Primary IgA Nephropathy (IgAN)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ARGX-121
  • Sponsor:Argenx

A Phase 3 Study of Once‑Daily Treprostinil Palmitil Inhalation Powder for Adults with Pulmonary Arterial Hypertension

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Obesity

Recruiting

Long‑term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity and Type 2 Diabetes

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Faenza

What the registry says about research in the country

01 Oncology Research - Lung Cancer

Innovative clinical trials focusing on non-small cell lung cancer and small-cell lung cancer, evaluating novel combination therapies and targeted treatments.

  • Advanced NSCLC treatment studies
  • KRAS G12C mutation therapies
  • Immunotherapy combinations

Multiple studies examining maintenance therapies and first-line treatment options for lung cancer patients.

02 Gynecologic Oncology

Comprehensive research in ovarian cancer, including studies on maintenance therapies and novel treatment approaches for recurrent disease.

  • BRCA-related treatments
  • Advanced peritoneal cancer
  • Endometrial cancer therapies

Investigations into new therapeutic combinations and targeted treatments for gynecologic malignancies.

03 Gastrointestinal Cancer Research

Studies examining treatments for various gastrointestinal cancers, including innovative approaches for colorectal and gastric cancers.

  • Microsatellite instability studies
  • Biliary tract cancer treatments
  • Immunotherapy applications

Focus on personalized treatment approaches and combination therapies for GI tract malignancies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.